Phase 3
Completed N=230
Administration of Ketamine to Prevent the Post-operative Pain
Source: ClinicalTrials.gov NCT00210210 ↗Enrolled (actual)
230
Serious AEs
0.0%
Results posted
Sep 2025
Primary outcomePrimary: Morphine Consumption (First 48 Post-operative Hours) — 79; 77 Participants
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
The surgery of breast cancer is responsible for post-operative pain, needing in about 30% some morphine consumption; like that, the association of ketamine with general anaesthesia may decrease morphine's use and so its adverse effects. The purpose is to evaluate the analgesic effect of a receptor NMDA's antagonist ( ketamine)
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Morphine Consumption (First 48 Post-operative Hours) |
79; 77 | — |
| SECONDARY Post-operative Pain |
106; 102; 3; 2 | — |
Eligibility Criteria
Inclusion criteria
- Patients 18 years older
- ASA class 1 or 2
- with surgery of breast cancer (mastectomy or tumorectomy)
Exclusion criteria
.Kétamine hypersensitivity
- Major psychiatric disorders
- Major cardio-vascular disorders
- Major neurologic disorders
- Major ocular disorders
- Morphine in pre-operative period
Data sourced from ClinicalTrials.gov (NCT00210210). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.